Personligt login

   Sekretariat/Secretariat:
   Vognmagergade 7, 3. sal
   1120 København K
   CVR:11089372

   Denne email adresse bliver beskyttet mod spambots. Du skal have JavaScript aktiveret for at vise den.
   Denne email adresse bliver beskyttet mod spambots. Du skal have JavaScript aktiveret for at vise den.

2016 European Guidelines on cardiovascular disease prevention in clinical practice

Guidelines er godkendt af DCS 12. januar 2017. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Guidelines er godkendt af DCS 12. januar 2017. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Guidelines er godkendt af DCS 12. januar 2017. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Guidelines er godkendt af DCS 12. januar 2017. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2015 ESC Guidelines for the management of infective endocarditis

Infective endocarditis (IE) is a deadly disease. Despite improvements in its management, IE remains associated with high mortality and severe complications. Until recently, guidelines on IE were mostly based on expert opinion because of the low incidence of the disease, the absence of randomized trials and the limited number of meta-analyses.

The main objective of the current Task Force was to provide clear and simple recommendations, assisting healthcare providers in their clinical decision making. These recommendations were obtained by expert consensus after thorough review of the available literature. An evidence-based scoring system was used, based on a classification of the strength of recommendations and the levels of evidence.

Guidelines er godkendt af DCS 7. januar 2016. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

The present document has been conceived as the European update to the American College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD). In light of the very recent consensus documents for the management of patients with VA released by the major international heart rhythm societies, the ESC Guidelines Committee decided to focus the content of this document on the prevention of SCD. The update is timely, considering the new insights into the natural history of diseases predisposing to SCD and the completion of major studies that will impact management strategies for heart failure (HF) involving both drug and device therapies.

Guidelines er godkendt af DCS 7. januar 2016. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2015 ESC Guidelines for the diagnosis and management of pericardial diseases

Pericardial diseases may be either isolated disease or part of a systemic disease. The main pericardial syndromes that are encountered in clinical practice include pericarditis (acute, subacute, chronic and recurrent), pericardial effusion, cardiac tamponade, constrictive pericarditis and pericardial masses. All medical therapies for pericardial diseases are off-label, since no drug has been registered until now for a specific pericardial indication. Significant new data have become available since 2004, and a new version of guidelines has become mandatory for clinical practice.

Guidelines er godkendt af DCS 7. januar 2016. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

The clinical spectrum of non-ST-elevation ACS (NSTE-ACS) may range from patients free of symptoms at presentation to individuals with ongoing ischaemia, electrical or haemodynamic instability or cardiac arrest. The pathological correlate at the myocardial level is cardiomyocyte necrosis [NSTE-myocardial infarction (NSTEMI)] or, less frequently, myocardial ischaemia without cell loss (unstable angina). A small proportion of patients may present with ongoing myocardial ischaemia, characterized by one or more of the following: recurrent or ongoing chest pain, marked ST depression on 12-lead ECG, heart failure and haemodynamic or electrical instability. Due to the amount of myocardium in jeopardy and the risk of malignant ventricular arrhythmias, immediate coronary angiography and, if appropriate, revascularization are indicated.

Guidelines er godkendt af DCS 7. januar 2016. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. The composition of the guidelines task force reflects the multidisciplinary nature of PH, including members of different medical societies, associations and working groups. The current document follows the two previous ESC and ERS Guidelines, published in 2004 and 2009, focusing on clinical management of PH. A systematic literature review was performed from MEDLINE® to identify new studies published since 2009 concerning the topic of PH. Task force members selected studies based on relevance and appropriateness.

Guidelines er godkendt af DCS 7. januar 2016. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne samlet i nedenstående dokument.

icon Kommentarer til ESC Guidelines

Link til ESC Guidelines

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management

The present Guidelines focus on the cardiovascular management of patients in whom heart disease is a potential source of complications during non-cardiac surgery. The risk of perioperative complications depends on the condition of the patient before surgery, the prevalence of comorbidities, and the urgency, magnitude, type, and duration of the surgical procedure.

These Guidelines are intended for physicians and collaborators involved in the pre-operative, operative, and post-operative care of patients undergoing non-cardiac surgery. The objective is to endorse a standardized and evidence-based approach to perioperative cardiac management.

Guidelines er godkendt af DCS 8. januar 2015. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent slides, CME test mm. hos ESC

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

This document follows the two previous ESC Guidelines focussing on clinical management of pulmonary embolism, published in 2000 and 2008. Many recommendations have retained or reinforced their validity; however, new data has extended or modified our knowledge in respect of optimal diagnosis, assessment and treatment of patients with PE.

These new aspects have been integrated into previous knowledge to suggest optimal and—whenever possible—objectively validated management strategies for patients with suspected or confirmed pulmonary embolism.

Guidelines er godkendt af DCS 8. januar 2015. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent summay, slides, CME test mm. hos ESC

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

Uniquely for a common cardiovascular disease, there are very few randomized, controlled, clinical trials in patients with HCM. For this reason, the majority of the recommendations in this document are based on observational cohort studies and expert consensus opinion. The aim is to provide healthcare professionals with a practical diagnostic and treatment framework for patients of all ages and, as the majority of patients have a genetic cause for their disease, the Guidelines also consider the implications of a diagnosis for families and provide specific advice on reproduction and contraception.

Adoption of a purely morphological disease definition means that the number of possible aetiologies is considerable, particularly in young children. As it is impractical to provide an exhaustive compendium of all possible causes of HCM, the Guidelines focus on the most common genetic and non-genetic subtypes, but additional references for less common disorders are provided. Similarly, treatment recommendations focus largely on generic management issues but make reference to rare diseases when appropriate.

Guidelines er godkendt af DCS 8. januar 2015. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent summay, slides, CME test mm. hos ESC

2014 ESC/EACTS Guidelines on myocardial revascularization

Myocardial revascularization has been subject to more randomized clinical trials (RCTs) than almost any other intervention. In order to inform the current Guidelines, this Task Force performed a systematic review of all RCTs performed since 1980, comparing head-to-head the different revascularization strategies—including CABG, balloon angioplasty, and PCI with bare-metal stents (BMS) or with various US Food and Drug Administration-approved drug-eluting stents (DES)—against medical treatment as well as different revascularization strategies, and retrieved 100 RCTs involving 93 553 patients with 262 090 patient-years of follow-up.

Formulation of the best possible revascularization approach, also taking into consideration the social and cultural context, will often require interaction between cardiologists and cardiac surgeons, referring physicians, or other specialists as appropriate. Patients need help with taking informed decisions about their treatment and the most valuable advice will probably be provided to them by the ‘Heart Team’.

Recognizing the importance of the interaction between cardiologists and cardiac surgeons, the leadership of both the ESC and the EACTS has given this Joint Task Force, along with their respective Guideline Committees, and the reviewers of this document the mission to draft balanced, patient-centred, evidencedriven practice guidelines on myocardial revascularization.

Guidelines er godkendt af DCS 8. januar 2015. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent CME test mm. hos ESC

2014 ESC Guidelines on the diagnosis and treatment of aortic diseases

In addition to coronary and peripheral artery diseases, aortic diseases contribute to the wide spectrum of arterial diseases: aortic aneurysms, acute aortic syndromes (AAS) including aortic dissection (AD), intramural haematoma (IMH), penetrating atherosclerotic ulcer (PAU) and traumatic aortic injury (TAI), pseudoaneurysm, aortic rupture, atherosclerotic and inflammatory affections, as well as genetic diseases (e.g. Marfan syndrome) and congenital abnormalities including the coarctation of the aorta (CoA).

Similarly to other arterial diseases, aortic diseases may be diagnosed after a long period of subclinical development or they may have an acute presentation. Acute aortic syndrome is often the first sign of the disease, which needs rapid diagnosis and decisionmaking to reduce the extremely poor prognosis.

These Guidelines are the result of a close collaboration between physicians from many different areas of expertise: cardiology, radiology, cardiac and vascular surgery, and genetics. We have worked together with the aim of providing the medical community with a guide for rapid diagnosis and decision-making in aortic diseases.

Guidelines er godkendt af DCS 8. januar 2015. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent summay, slides, CME test mm. hos ESC

Diabetes, Pre-Diabetes and Cardiovascular Diseases

This is the second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidencebased management decisions. The growing awareness of the strong biological relationship between DM and CVD rightly prompted these two large organizations to collaborate to generate guidelines relevant to their joint interests, the first of which were published in 2007. Some assert that too many guidelines are being produced but, in this burgeoning field, five years in the development of both basic and clinical science is a long time and major trials have reported in this period, making it necessary to update the previous Guidelines.

Guidelines er godkendt af DCS 9/1 2014. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent summary card, slides, CME test mm. hos ESC

Arterial Hypertension (Management of)

The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) follow the guidelines jointly issued by the two societies in 2003 and 2007.1,2 Publication of a new document 6 years after the previous one was felt to be timely because, over this period, important studies have been conducted and many new results have been published on both the diagnosis and treatment of individuals with an elevated blood pressure (BP), making refinements, modifications and expansion of the previous recommendations necessary.

Guidelines er godkendt af DCS 9/1 2014. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent summary card, CME test mm. hos ESC

Stable Coronary Artery Disease (Management of)

These guidelines should be applied to patients with stable known or suspected coronary artery disease (SCAD). This condition encompasses several groups of patients: (i) those having stable angina pectoris or other symptoms felt to be related to coronary artery disease (CAD) such as dyspnoea; (ii) those previously symptomatic with known obstructive or non-obstructive CAD, who have become asymptomatic with treatment and need regular follow-up; (iii) those who report symptoms for the first time and are judged to already be in a chronic stable condition (for instance because history-taking reveals that similar symptoms were already present for several months). Hence, SCADdefines the different evolutionary phases of CAD, excluding the situations in, which coronary artery thrombosis dominates clinical presentation (acute coronary syndromes).

Guidelines er godkendt af DCS 9/1 2014. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent slides, CME test mm. hos ESC

Cardiac Pacing and Cardiac Resynchronization Therapy

The 2013 guidelines, revised for the first time since 2007, were developed with input from 70 clinicians, including an expert Task Force of 18 cardiologists specialising in cardiac pacing and resynchronisation, a further 26 experts in the field who reviewed the document, with the entire process overseen by the ESC Committee for Practice Guidelines (CPG).

The first part of the guidelines explores indications for pacing in patients who have cardiac arrhythmias. The second part looks at indications for cardiac resynchronisation therapy in heart failure. The third part includes indications for pacing in specific conditions, such as acute MI, pacing after cardiac surgery, TAVI and heart transplantation, and pacing in children and individuals with congenital heart diseases. Finally, the guidelines explore management considerations such as re implantation after device explanation for infection, magnetic resonance imaging in patients with implanted cardiac devices, emergency (transvenous) temporary pacing and remote management of arrhythmias and devices.

Guidelines er godkendt af DCS 9/1 2014. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.

icon Hent godkendte guidelines inkl. danske kommentarer

Hent CME test, slides mm. hos ESC

Valvular Heart Disease (Management of)

Although valvular heart disease (VHD) is less common in industrialized countries than coronary artery disease (CAD), heart failure, or hypertension, guidelines are of interest in this field because VHD is frequent and often requires intervention.

These guidelines focus on acquired VHD, are oriented towards management, and do not deal with endocarditis or congenital valve disease, including pulmonary valve disease, since recent guidelines have been produced by the ESC on these topics.

Guidelines er godkendt af DCS 10/1 2013. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (4.13 MB)

Hent resume, CME test, slides mm. hos ESC 

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

In 2010, when the ESC Guidelines for the Management of Atrial Fibrillation were first issued, it was already realized that an update
would be necessary in 2012 because, for example, European regulatory approvals of several new drugs were anticipated, such as vernakalant and dabigatran. In addition, reports from major clinical trials of the novel oral anticoagulants, such as AVERROES (Apixaban VErsus acetylsalicylic acid (ASA) to Reduce the Rate Of Embolic Stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment), ROCKET-AF (Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation), and ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation), were expected, paving the way for potentially yet more regulatory approvals.

Clinical outcomes research in AF continues at a fast pace. Also, considerably more clinical experience has been gathered in the fields of anticoagulation, atrial appendage occlusion, antiarrhythmic drug use for cardioversion and rhythm control, and left atrial ablation. These five areas form the bulk of the revisions to our recommendations.

Guidelines er godkendt af DCS 10/1 2013. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (1.63 MB)

Hent corrigendum, CME test, slides mm. hos ESC

Third Universal Definition of Myocardial Infarction

In 2000, the First Global MI Task Force presented a new definition of MI, which implied that any necrosis in the setting of myocardial ischaemia should be labelled as MI. These principles were further refined by the Second Global MI Task Force, leading to the Universal Definition of Myocardial Infarction Consensus Document in 2007, which emphasized the different conditions which might lead to an MI. This document, endorsed by the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF), has been well accepted by the medical community and adopted by the WHO.

However, the development of even more sensitive assays for markers of myocardial necrosis mandates further revision, particularly when such necrosis occurs in the setting of the critically ill, after percutaneous coronary procedures or after cardiac surgery. The Third Global MI Task Force has continued the Joint ESC/ACCF/AHA/WHF efforts by integrating these insights and new data into the current document, which now recognizes that very small amounts of myocardial injury or necrosis can be detected by biochemical markers and/or imaging.

Guidelines er godkendt af DCS 10/1 2013. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines. 

icon Hent godkendte guidelines inkl. danske kommentarer (2.31 MB)

Hent CME test, slides mm. hos ESC

CVD Prevention in clinical practice (European Guidelines on)

CVD is strongly connected to lifestyle, especially the use of tobacco, unhealthy diet habits, physical inactivity, and psychosocial stress. The World Health Organization (WHO) has stated that over three-quarters of all CVD mortality may be prevented with adequate changes in lifestyle. CVD prevention, remaining a major challenge for the general population, politicians, and healthcare workers alike, is defined as a co-ordinated set of actions, at public and individual level, aimed at eradicating, eliminating, or minimizing the impact of CVDs and their related disability. The bases of prevention are rooted in cardiovascular epidemiology and evidence-based medicine.

The aim of the 2012 guidelines from the Fifth Joint Task Force (JTF) of the European Societies on Cardiovascular Disease Prevention in Clinical Practice is to give an update of the present knowledge in preventive cardiology for physicians and other health workers.

Guidelines er godkendt af DCS 10/1 2013. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (5.14 MB)

Hent resume, CME test mm. hos ESC

Acute and Chronic Heart Failure

The aim of this document is to provide practical, evidence-based guidelines for the diagnosis and treatment of heart failure (HF).

The principal changes from the 2008 guidelines relate to:

 (i) an expansion of the indication for mineralocorticoid (aldosterone) receptor antagonists (MRAs);
(ii) a new indication for the sinus node inhibitor ivabradine;
(iii) an expanded indication for cardiac resynchronization therapy (CRT);
(iv) new information on the role of coronary revascularization in HF;
(v) recognition of the growing use of ventricular assist devices and
(vi) the emergence of transcatheter valve interventions.

There are also changes to the structure and format of the guidelines. Therapeutic recommendations now state the treatment effect supported by the class and level of recommendation in tabular format; in the case of chronic heart failure due to left ventricular (LV) systolic dysfunction, the recommendations focus on mortality and morbidity outcomes.

Guidelines er godkendt af DCS 10/1 2013. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (3.24 MB)

Hent corrigendum, CME test mm. hos ESC

Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of)

The management of acute myocardial infarction continues to undergo major changes. Good practice should be based on sound evidence, derived from well-conducted clinical trials. Because of the great number of trials on new treatments performed in recent years, and in view of new diagnostic tests, the ESC decided that it was opportune to upgrade the previous guidelines and appointed a Task Force.

The present guidelines pertain to patients presenting with ischaemic symptoms and persistent ST-segment elevation on the electrocardiogram (ECG). Most of these patients will show a typical rise in biomarkers of myocardial necrosis and progress to Q-wave myocardial infarction.

Guidelines er godkendt af DCS 10/1 2013. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (2.85 MB)

Hent resume, CME test, powerpoint slides mm. hos ESC

Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation (Management of)

The present document deals with the management of patients with suspected NSTE-ACS, replacing the document first published in 2000 and updated in 2002 and 2007. It includes all scientific evidence fully published as peer-reviewed papers, before May 2011.

Guidelines er godkendt af DCS 12/1 2012. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (3.1 MB)

Hent appendiks, CME test, powerpoint slides mm. hos ESC

Dyslipidaemias (Management of)

These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.

Guidelines er godkendt af DCS 12/1 2012. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (6.67 MB)

Hent appendiks, CME test mm. hos ESC

Cardiovascular Diseases during Pregnancy (Management of) 2011

At present, 0.2–4% of all pregnancies in western industrialized countries are complicated by cardiovascular diseases (CVD) and the number of the patients who develop cardiac problems during pregnancy is increasing. Nevertheless, the number of such patients presenting to the individual physician is small. However, knowledge of the risks associated with CVD during pregnancy and their management are of pivotal importance for advising patients before pregnancy. Therefore, guidelines on disease management in pregnancy are of great relevance.

Guidelines er godkendt af DCS 12/1 2012. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (1.56 MB)

Hent resume, smartphone-version, powerpoint slides mm. hos ESC

Device Therapy in Heart Failure (Focused Update) 2010

An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy.

Guidelines er godkendt af DCS 13/1 2011. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (790.5 kB)

Myocardial Revascularisation (ESC Guideline for) 2010

Myocardial revascularization has been an established mainstay in the treatment of CAD for almost half a century. Coronary artery bypass grafting (CABG), used in clinical practice since the 1960s, is arguably the most intensively studied surgical procedure ever undertaken, while percutaneous coronary intervention (PCI), used for over three decades, has been subjected to more randomized clinical trials (RCTs) than any other interventional procedure. Recognizing the importance of the interaction between (interventional) cardiologists and cardiac surgeons, the leadership of both the ESC and EACTS has given this Joint Task Force, their respective Guideline Committee, and the reviewers of this document the mission to draft balanced, patient-centred, evidencedriven practice guidelines on myocardial revascularization.

Guidelines er godkendt af DCS 13/1 2011. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (2.83 MB)

 Hent smartphone-version, powerpoint slides mm. hos ESC

Atrial Fibrillation (Management of) 2010

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. Over 6 million Europeans suffer from this arrhythmia, and its prevalence is estimated to at least double in the next 50 years as the population ages. It is now 4 years since the last AF guideline was published, and a new version is now needed. AF confers a 5-fold risk of stroke, and one in five of all strokes is attributed to this arrhythmia. Ischaemic strokes in association with AF are often fatal, and those patients who survive are left more disabled by their stroke and more likely to suffer a recurrence than patients with other causes of stroke. In consequence, the risk of death from AF-related stroke is doubled and the cost of care is increased 1.5-fold. There has been much research into stroke prevention, which has influenced this guideline.

Guidelines er godkendt af DCS 13/1 2011. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (3.1 MB)

 Hent resume, smartphone-version, powerpoint slides mm. hos ESC

Grown-Up Congenital Heart Disease (Management of) 2010

Precise data on the size and composition of the GUCH population are still lacking and can be assumed to change constantly. The remarkable improvement in survival of patients with CHD has led to a continuously growing number of GUCH patients, in particular those with more complex disease. The present document refers to the previous ESC guidelines where recommendations for the transition from paediatric to adult care, the infrastucture and network of specialist GUCH centres with models of delivery, the actual delivery of patient care, and the requirements for training are covered in more detail. The previous guidelines stratified patient care into three levels: (i) patients who require care exclusively in the specialist centre; (ii) patients in whom shared care can be established with the appropriate general adult cardiac services; and (iii) patients who can be managed in ‘nonspecialist’ clinics (with access to specialized care if required). The current document in general did not attempt to assign a certain level of care just by diagnosis.

Guidelines er godkendt af DCS 13/1 2011. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning. Dette nummer genfindes på relevant plads i den engelsksprogede udgave af guidelines.

icon Hent godkendte guidelines inkl. danske kommentarer (2.26 MB)

 Hent smartphone-version, powerpoint slides mm. hos ESC

Pre-operative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-Cardiac Surgery

”Pre-operative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-Cardiac Surgery” er fremlagt godkendelse af DCS på Efterårsmødet 28/10 2010. Godkendelsen repræsenterer DCSs officielle holdning på dette område.

icon Hent godkendte guidelines (1.54 MB)

 Hent resume, smartphone-version, powerpoint slides mm. hos ESC

Guidelines for the diagnosis and management of syncope (version 2009)

The first ESC Guidelines for the management of syncope, were published in 2001, and reviewed in 2004.1 In March 2008, the CPG considered that there were enough new data to justify production of new guidelines.

The most relevant changes are listed here:

† An update of the classification of syncope in the larger framework of transient loss of consciousness (T-LOC).

† New data on epidemiology.

† A new diagnostic approach focusing on risk stratification of sudden cardiac death (SCD) and cardiovascular events after initial evaluation, including some recommendations for treatment in patients with unexplained syncope at high risk.

† Emphasis on the increasing role of a diagnostic strategy based on prolonged monitoring in contrast to the conventional strategy based on laboratory testing.

† An update of evidence-based therapy.

Rapporten er fremlagt til diskussion på DCS årsmøde 2010.

icon Hent de godkendte ESC guidelines (2.51 MB)

 Hent resume, smartphone-version, powerpoint slides mm. hos ESC

Ændringer i kliniske retningslinjer for forebyggelse af CVD fra 2003 til 2007

I september 2007 udkom den 4. reviderede udgave af de europæiske anbefalinger for forebyggelse af kardiovaskulær sygdom (CVD).

Målet med de europæiske retningslinjer er, at de implementeres nationalt tillempet de enkelte landes muligheder. Styrken er at retningslinjerne er opnået på basis af en bred tværfaglig arbejdsgruppe forankret i europæiske/internationale selskaber med særligt fokus på at involvere de faggrupper, der foretager forebyggelsessamtaler og initierer livsstilsændringer, – sygeplejersker og praktiserende læger. Den tværfaglige danske arbejdsgruppe er nedsat på initiativ af Dansk Cardiologisk Selskab.

Den danske arbejdsgruppe har denne gang valgt kun at fokusere på de væsentligste ændringer og tilpasset disse ændringer til danske forhold.

Lia E. Bang, Gudrun Boysen, Bo Christensen, Hanne K. Rasmusen (formand), Ole Snorgaard og Henrik Sillesen

Rapporten er fremlagt til diskussion på DCS Efterårsmøde 2008.

icon Hent rapporten: Ændringer i kliniske retningslinjer for forebyggelse af CVD fra 2003 til 2007 (174.49 kB)

icon Hent de godkendte ESC guidelines (6.85 MB)

 Hent resume, smartphone-version, powerpoint slides mm. hos ESC

Endorsed ESC rapporter